Background: To critically assess the evidence of integrated Chinese and western medicine for treating Menopausal syndrome (MPS).
Introduction
Menopausal syndrome (MPS), also known as perimenopausal syndrome (PPS), is an autonomic nervous system dysfunction associated with neuropsychological syndromes, which results from the declining of ovarian function and the estrogen levels during the pre-or postmenopausal phases (Yu et al., 2012) . MPS mostly occurs in women around 45-55 years of age. According to the reports, about 90% women who suffered from menopause may present one or more symptoms (Zhou et al., 2003) . It does not only affect the female physical and mental health, but also their work, family life and interpersonal relationships.
A lot of groups reported that the average age of women with natural menopause is between 49 to 51 years of age. The median age of menopause is about 50-52 years in the developed countries, 47 years in Asia, 47 years in developing countries, and 47.5-49.5 years in China. medicine with that of western medicine alone in patients with menopausal syndrome, between the ages of 40 to 55. The included RCTs had to report the diagnostic criteria clearly. There were no restrictions on population characteristics, language and publication type. Outcome measures included the total effective rate, the levels of serum hormones i.e. FSH, LH, E2, Kupperman score，as well as the scale for TCM syndrome and symptom differentiation (TCM-SSD) scores and so forth. The criteria "recovery, obviously effective, effective, or ineffective" was also included in the outcome measurement. All the included literature reported two evaluation indexes at the least. Duplicated publications reporting the same groups of participants were excluded.
Trial Quality Assessment
Two authors (Liu and Kou) evaluated the quality of the included trials. The quality of included trials was evaluated and scored according to Jadad evaluation standards (Jadad et al., 1996) to address the following four criteria: Randomization (appropriate: 2 points, unclear: 1point, inappropriate: 0 point), Concealment of allocation (appropriate: 2 points, unclear: 1point, inappropriate: 0 point), Double blinding (double blinding and description: 2 points, double blinding and description was unclear: 1point, No blind or no description: 0 point), Withdraws and dropouts (Description: 1point, no description: 0 point). The scores ranged from 1 to 7 points, of1-3scores belonged to poor quality studies of 4-7 scores classified into high quality studies.
Data Analysis
The statistical package (RevMan 5.0) provided by the Cochrane Collaboration was used for data analyses. Dichotomous data were presented as risk ratio (RR) and continuous outcomes as Standard Mean Difference (SMD), both with 95% confidence interval (CI).Meta-analysis was performed if the intervention, control, and outcome were the same or similar. The statistical heterogeneity was presented as significant when I square (I 2 ) is over 50% or P<0.1.Random effect model was used for the meta-analysis if there was significant heterogeneity (I 2 >50%) and fixed effect model was used when the heterogeneity was not significant (I 2 <50%) (Zhai et al. 2001).
Results

Description of Included Studies
The flow chart depicts the whole search process and study selection ( Figure 1 ). After searching the six databases, 507 citations were screened. The vast majority of them were excluded due to obvious ineligibility that included irrelevant titles and abstracts (some pieces of literature were accessed from more than one database) after reading the titles and abstracts. 
Methodological Quality
According to the predefined quality assessment criteria, the majority of the included trials assessed were of generally poor methodological 
Effect Estimates
The General Effective Rate
The total effective rate was deemed as the combination of "cure" and "significant effect" with "effective rate". These different kinds of . Although there were no significant differences in elevating E2 levels between two treatments, the trends appearing in the management using the integrated Chinese and western medicine was undeniably better than the western medicine alone. 
Publication Bias
While comparing the integrated Chinese and western medicine versus western medicine alone, a funnel plot analysis revealed a serious asymmetry in the general effective rate among the 11 trials (Figure 7 ). (Table 3) . Chinese and western medicine therapy to treat MPS, and in fact the available research has shown that the integrated medicine approach has an excellent effect in treating MPS. This is because this therapy is not only able to alleviate MPS, but also reduce the side effects of hormone replacement, such as the distending pain of breast and the endometrial thickening. Furthermore, it can enhance the therapeutic security to a greater extent (Chen et al., 2003) .
The results of this review show that the therapeutic effect of integrated Chinese and western medicine is superior to that of western medicine alone, in relieving the symptoms, decreasing the FSH levels and improving clinical efficiency. While, there was no significant difference between the two therapeutic methods in regulating the levels of LH and E2 in patients, the clinical efficiency of integrated Chinese and western medicine was undeniably better than the western medicine alone. Due to the limitations regarding the included literature for this evaluation, we cannot draw firm conclusions about the efficacy of the treatment of MPS with integrated Chinese and western medicine.
The obtained literature for RCTs in treating MPS with integrated Chinese and western medicine was published only in Chinese, while the methodology of the clinical trials described was of generally poor quality. The methods for randomization and allocation concealment in these trails were mainly described inadequately or incompletely. Most randomized studies failed to follow any standard. For example, only 2 out of the included 12 trials mentioned using single blind method, but without providing sufficient information. Although the TCM therapy is difficult to be blind, the researchers should correctly apply randomization, and make a detailed record of withdrawal, dropout and long-term follow-up. In addition, since these factors are closely related to the effect of the examined therapies, they may result in no statistical difference and selective bias. In summary, we need high-quality clinical trials to evaluate the curative effect of integrated Chinese and western medicine in patients with MPS, even though abundant clinical experiences, especially case reports, have been repeatedly published for decades (Chen et al., 2001; Chen et al., 2006) . Therefore, a perfect, multi-centered and larger sample size of trials is required for providing better evidence-based medicine (EBM)
confirmation.
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